free radicals generated by oxidative stress. 7, 8 Overcoming this limitation could improve the effectiveness of stem cell therapy for cardiac disease. One strategy is to genetically manipulate the expression of key genes involved in cell survival. Prosurvival genes, such as Akt, B-cell lymphoma 2, SDF-1, and chemokine (c-c motif) receptor 1, have been tested to improve stem cell viability after transplantation but with little efficacy. 4, 9 In this study, we tested a new target gene, oxygen-dependent prolyl hydroxylase domain protein 2 (PHD2) that regulates 2 key transcription factors involved in cell survival and inflammation: hypoxiainducible factor-1α (HIF-1α) and nuclear factor-κB (NF-κB). 10 Under normoxia, PHD2 hydroxylates HIF-1α leading to its ubiquitination and degradation, 11 and thus, HIF-1α has a short half-life of ≈5 minutes. Hypoxia decreases the activity of PHD2, resulting in less hydroxylation and increased HIF-1α abundance. However, elevated HIF-1α is not stable because reoxygenation easily causes its degradation, which hampers HIF-1α-induced cytoprotection. 12 HIF-1α is required for survival of stem cells, 13, 14 and hypoxic preconditioning promotes stem cell survival through an HIF-1α-dependent mechanism. 15 Reducing PHD2 activity induced by hypoxia also enhances inhibitor of nuclear factor κB (IκB) kinase activity that activates NF-κB. 16 In stem cells, it has been shown that the activation of NF-κB promotes not only survival, but also the secretion of cytokines/growth factors. 17 This study tests the hypothesis that PHD2 silencing enhances stem cell survival and paracrine function after transplantation, enhancing protection and repair of the damaged heart. Short hairpin RNA was used to silence PHD2 in human adipose-derived stem cells (ADSCs) that were then injected into a mouse MI model. ADSCs were used because they are easily obtained and abundant, and that they can be used without expansion, [18] [19] [20] in addition to having the potential of autologous administration or low immunogenicity when used heterologously. 21 The experiments performed showed that ADSC administration promoted angiogenesis and reduced myocardial inflammation, infarct size, and fibrosis, leading to improved cardiac function. PHD2 silencing in ADSCs enhanced cardioprotection by promoting ADSC survival through an HIF-1α-dependent pathway and ADSC secretion of insulin-like growth factor-1 (IGF-1) via an NF-κB-mediated mechanism. These results suggest that PHD2 silencing in ADSCs enhances their therapeutic efficacy in the infarcted heart.
Methods
Human ADSCs were isolated and cultured as previously described. 20 ADSCs of passage 3 were used for this study. ADSCs were infected with lentiviruses containing short hairpin RNA-encoding sequences for PHD2 or HIF-1α at the multiplicity of infection of 10 and stably transduced. ADSCs were enriched by cell sorting with FACS Aria II (BD Biosciences) for transplanting into infarcted hearts or further culture. PHD2 silencing and its effect on HIF-1α abundance were confirmed by Western blotting. Permanent ligation of left anterior descending coronary artery and cell injection were performed in male C57 mice (8 weeks old). Immediately after coronary ligation, 1×10 5 ADSCs suspended in 50 μL PBS were injected at 5 sites in the anterior and posterior infarct border zones of the ischemic myocardium. FK506 (3 mg/kg per day, IP, Sigma) was administered to ADSC-transplanted and sham-operated animals daily from 1 week before the operation until the end of the study. Animal care and all experimental procedures were performed in strict accordance with the approved protocols and animal welfare regulations of the Animal Care and Use Committee at Third Military Medical University. Echocardiography was used to measure cardiac function, and immunohistology (Masson trichrome, terminal deoxynucleotidyl transferase dUTP nick-end labeling [TUNEL]) was performed to determine cardiac remodeling. Triphenyltetrazolium chloride staining was performed to evaluate the infarction size. Cultured ADSCs, with or without PHD2 silencing or neonatal rat ventricular myocytes, (NRVMs), were challenged with H 2 O 2 . To test the protective effect of paracrine factors secreted by ADSCs against H 2 O 2 -induced cell death, conditioned medium (CM) from ADSC cultures was added to NRVMs. Western blotting of activated caspase-3 and TUNEL and annexin V staining were used to determine the antiapoptotic effects of PHD2 silencing in ADSCs and CM on NRVMs. Cell counting kit-8 assay and [ 3 H]-thymidine assay were performed to detect the proliferation of ADSCs. A `cell sorter analysis was used to determine the percentage of green fluorescent protein (GFP) + cells isolated from ADSC-injected hearts and annexin V-positive cells. To identify cytokines/growth factors secreted by ADSCs, Human Cytokine Antibody Array C (series 2000 membranes, Ray Biotech) targeting 79 secreted factors was executed. ELISA was performed to further measure the concentrations of identified cytokines/growth factors. A chromatin immunoprecipitation assay was performed to detect the association between IGF-1 promoter and NF-κB. Student t test or 1or 2-way ANOVA with the Bonferroni post hoc test was performed to determine statistical significance (P<0.05). An expanded Methods section is available in the Online Data Supplement.
Results

Expression of PHD2 in ADSCs Transduced With Lentiviral shPHD2-GFP
Primary cultured ADSCs of passage 3 were characterized by multipotent differentiation potential and surface markers. Similar to a previous study, 20 ADSCs maintained the potential to differentiate into adipocytes and osteoblasts, demonstrating their multilineage differentiation potential. As shown in Online Figure IA, ADSCs treated with lipogenic medium for 3 weeks were stained with Oil Red O to mark neutral lipids in the cytoplasm; ADSCs treated with osteogenic medium for 3 weeks were stained with Alizarin red to mark mineralized matrix. Flow cytometry demonstrated that these cells were positive for stem cell markers, CD90 + , CD73 + , CD44 + , and CD105 + , but negative for hematopoietic lineage markers, CD45 − and CD34 − (Online Figure I B) . These results indicated that these cells maintain a typical ADSC phenotype. 20 ADSCs were transduced with lentiviruses containing GFP or short hairpin RNA against prolyl hydroxylase domain protein 2 (shPHD2)-GFP constructs. Transduced ADSCs were enriched by fluorescence-activated cell sorting and then expanded in culture ( Figure 1A compared with GFP-ADSCs, but did not alter PHD1 and PHD3 protein abundance, documenting the specificity of the approach ( Figure 1B ).
Effects of shPHD2-GFP-ADSC Transplantation on Myocardial Infarct Size and Cardiac Function
To determine whether silencing of PHD2 generates an enhanced therapeutic effect of stem cells, we evaluated the effects of ADSC transplantation on infarct size and cardiac function in post-MI mouse hearts. The initial areas at risk (ie, the area of ischemia) of infarcted hearts in different groups are comparable (data not shown). Myocardial infarct size was significantly smaller in mice treated with shPHD2-GFP-ADSCs than in those with PBS and GFP-ADSCs at 4 weeks post-MI (Figure 2A and 2B). These data suggest that fewer cardiomyocytes in the areas at risk die after shPHD2-GFP-ADSC transplantation. Left ventricular fractional shortening and ejection fraction were greater in post-MI hearts treated with shPHD2-GFP-ADSCs at 4 weeks than in post-MI hearts treated with GFP-ADSCs or PBS. MI significantly decreased fractional shortening and ejection fraction in all groups of post-MI hearts compared with sham-operated hearts ( Figure 2C , 2E, and 2F). Diastolic left ventricular internal diameter of post-MI hearts at 4 weeks was significantly larger than that of sham hearts, indicating LV dilation induced by MI injury. shPHD2-GFP-ADSC but not GFP-ADSC transplantation significantly limited the increase of diastolic left ventricular internal diameter induced by MI ( Figure 2G ). These results show that ADSCs with shPHD2 reduce the post-MI deterioration of cardiac function, and this cardioprotective effect is significantly greater than that of ADSCs without shPHD2.
Effects of shPHD2-GFP-ADSC Transplantation on Post-MI Myocardial Remodeling and Inflammation
To determine the mechanisms underlying the protective effects of shPHD2-GFP-ADSC transplantation, TUNEL assay was used to measure apoptotic cell death in the infarct border zone. As shown in Figure 3A and Online Figure II , TUNEL + cardiomyocyte nucleus number per 10 6 nuclei was moderately reduced in GFP-ADSC-treated hearts and more significantly reduced in shPHD2-GFP-ADSC-treated hearts at 48 hours post-MI. Masson trichrome staining showed that there were increased islands of viable cardiac muscle in the peri-infarct regions at 4 weeks after ADSC treatment. The percentage of fibrotic area in the total peri-infarct zone was significantly reduced in ADSC-treated hearts, and shPHD2-GFP-ADSCs further reduced it ( Figure 3B and Online Figure III ). We also investigated the effects of shPHD2-GFP-ADSC transplantation on angiogenesis and inflammation in the post-MI hearts. At 4 weeks after transplantation, immunostaining showed more CD31-expressing capillaries being present in peri-infarct regions of ADSCs versus PBS-treated hearts ( Figure 3C ). However, there was no difference between GFP-ADSC and shPHD2-GFP-ADSC groups. Inflammatory cell infiltration was analyzed by flow cytometry at 48 hours after MI. ADSC transplantation reduced the percentage of CD11b + / Ly6C high cells, and shPHD2-GFP-ADSCs and GFP-ADSCs exerted comparable effects ( Figure 3D and Online Figure  IV) . These data suggest that the enhanced therapeutic effect of shPHD2-GFP-ADSC treatment for MI is associated with reduced cardiomyocyte apoptosis, along with a decrease in fibrosis, but not related to angiogenesis and inflammatory responses. 
Effect of PHD2 Silencing on ADSC Survival
As shown in Figure 4A , the transplanted GFP + cells were found in vivo by immunostaining. To quantify the survival of transplanted ADSCs, MI hearts were digested at 4 hours, 48 hours, and 7 days after transplantation. There were significantly more GFP + cells in the myocardium in the shPHD2-GFP-ADSC group compared with the GFP-ADSC group at 7 days after transplantation ( Figure 4B and 4C). The better survival rate of shPHD2-GFP-ADSCs was confirmed with fluorescence-activated cell sorter analysis of isolated GFP + cells at multiple time points after transplantation ( Figure 4D ). At 4 weeks posttransplantation, more shPHD2-GFP-ADSCs were engrafted in the myocardium than GFP-ADSCs (engraftment rate: 0.65±0.09% versus 0.12±0.04%; n=4; P<0.05). The increased percentage of shPHD2-GFP-ADSCs found in the MI heart does not seem to be caused by enhanced cell proliferation, assessed with cell counting kit-8 and [ 3 H]-thymidine assays (Online Figure V) .
Hypoxia and oxidative stress in the ischemic area of the post-MI heart are thought to be the main reasons for the death of resident cardiomyocytes and transplanted ADSCs. 7, 8 We used H 2 O 2 to treat ADSCs and cardiomyocytes to simulate oxidative stress in vitro. ADSC apoptosis was assessed by Western blotting of activated caspase-3 and fluorescence-activated cell sorting of annexin V staining. H 2 O 2 increased the ratio of activated caspase-3/total caspase-3 and annexin V-positive cells in all groups of ADSCs, but these increases were significantly blunted by PHD2 silencing (Figure 5A and 5B).
The mechanism involved in shPHD2-mediated cell protection against H 2 O 2 likely involves HIF-1α stabilization because HIF-1α prolyl hydroxylation by PHDs triggers proteasome targeting and protein degradation. 11 In the presence of H 2 O 2 , we found that HIF-1α protein abundance was increased 3.8fold in shPHD2-GFP-ADSCs compared with that in GFP-ADSCs ( Figure 5C ). Concomitantly, the mRNA levels of canonical HIF downstream targets erythropoietin and glucose transporter were found to be significantly increased in shPHD2-GFP-ADSCs ( Figure 5D ). Both the increases of HIF-1α and HIF-1α target mRNAs in shPHD2-GFP-ADSCs could be reduced by short hairpin RNA against hypoxia-inducible factor-1α treatment ( Figure 5C and 5D ). When HIF-1α was silenced in ADSCs, the antiapoptotic effect of shPHD2 on ADSCs was lost ( Figure 5E and 5F).
PHD2 Silencing Does Not Enhance Differentiation of ADSCs Into Cardiac Lineages
We determined the phenotypes of injected cells at 4 weeks after transplantation. A few ADSCs expressed von Willebrand factor or α-smooth muscle actin, indicating that some injected cells differentiated into endothelial cells and smooth muscle cells (Online Figure VIA and VIB) . The contribution of ADSCs to neoangiogenesis was demonstrated by the colocalization of vascular marker CD31 with GFP, indicating that the vessels incorporated with cells derived from transplanted ADSCs (Online Figure VII) . shPHD2 does not change the potential of ADSCs to form new vessels in the infarcted heart (rate of ADSCs expressed CD31: GFP-ADSCs, 9.54±2.23%; shPHD2-GFP-ADSCs, 9.91±2.08%; n=4; P>0.05). Because of the low survival rate of ADSCs at 4 weeks posttransplantation, the new vessels formed by ADSC differentiation were still rare, which amounted to very few of the angiogenesis.
In all treatment groups, no ADSC was found to express sarcomeric tropomyosin or α-actinin, suggesting that no mature cardiomyocyte differentiated from ADSCs (Online Figure  VIC) . Therefore, the enhanced beneficial effects on infarct 
PHD2 Silencing Enhances the Secretion of Antiapoptotic ADSC Paracrine Factors to Protect Cardiomyocytes
PHD2 silencing in ADSCs could protect the post-MI heart via a paracrine mechanism. This idea was tested by defining the effects of CM from ADSCs with or without shPHD2 on H 2 O 2induced cardiomyocyte apoptosis. Treatment of NRVMs with 100 μmol/L H 2 O 2 for 6 hours caused significant activation of caspase-3. GFP-ADSCs-CM moderately decreased activated caspase-3 of NRVMs, but it was significantly decreased by shPHD2-GFP-ADSC-CM ( Figure 6A ). GFP-ADSC-CM decreased TUNEL + cells compared with NRVMs treated with H 2 O 2 alone, and shPHD2-GFP-ADSC-CM further decreased TUNEL + cardiomyocytes ( Figure 6B ). These data suggest that CM of ADSCs exerts antiapoptotic effects on injured cardiomyocytes, and this beneficial effect is significantly enhanced by PHD2 silencing.
PHD2 Silencing Enhances Protective Paracrine Effects of IGF-1 via an NF-κB-Dependent Mechanism in ADSCs
An antibody array detecting 79 cytokines/growth factors was used to identify cardioprotective factors secreted from shPHD2-GFP-ADSCs and GFP-ADSCs. Nine secreted factors were induced by shPHD2, with a >1.3-fold increase in 2 independent array analyses (Online Table I ). IGF-1 was increased by 3.30-fold and 4.32-fold in these 2 experiments, which was a greater increase than any other factor. ELISA analysis confirmed that IGF-1 was significantly upregulated in shPHD2-GFP-ADSC-CM, but the levels of other prosurvival cytokines vascular endothelial growth factor, hepatocyte growth factor, stromal cell-derived factor-1, and erythropoietin did not differ between the 2 groups of ADSCs ( Figure 7A-7E) .
To determine whether the enhanced cardioprotective effect of shPHD2-GFP-ADSC-CM is mediated by IGF-1, CM was treated with a neutralizing IGF-1 antibody. This treatment abrogated the decrease in activated caspase-3 and reduction of the TUNEL + NRVMs induced by shPHD2-GFP-ADSC-CM ( Figure 7F and 7G) . The IGF-1 antibody alone neither influenced the activation of caspace-3 nor did it change the TUNEL + rate in cardiomyocytes. These data suggest that IGF-1 is an important prosurvival cytokine associated with shPHD2-GFP-ADSCs. To determine whether enhanced IGF-1 secretion in shPHD2-GFP-ADSCs was mediated by HIF-1α stabilization, we prevented the increase in HIF-1α abundance in shPHD2-GFP-ADSCs with short hairpin RNA against hypoxia-inducible factor-1α. Double silencing of PHD2 and HIF-1α did not alter the IGF-1 concentration in CM ( Figure 7K ) nor did it change the capability of shPHD2-GFP-ADSC-CM to attenuate cardiomyocyte apoptosis (caspase-3 activation and TUNEL + rate; Figure 7H and 7I and Online Figure VIII) . These results indicate that HIF-1 signaling may not be involved in the antiapoptotic effect of shPHD2-GFP-ADSC-CM.
The NF-κB pathway is reported to be regulated by PHD2 16, 22, 23 and regulates the expression of IGF-1, independent of HIF-1α signaling. 24, 25 Therefore, we tested whether NF-κB activation accounts for the enhanced IGF-1 secretion of shPHD2-GFP-ADSCs. shPHD2 increased NF-κB activity ( Figure 7J ) and induced nuclear translocation of NF-κB in ADSCs (Online Figure IX) . These effects were blocked by NF-κB inhibitor BAY11-7082. We demonstrated that PHD2 silencing increased the phosphorylation of inhibitor of nuclear factor κB kinase and further increased the phosphorylation and degradation of IκBα, thereby activating NF-κB in ADSCs (Online Figure X) , similar to the previous finding. 16 BAY11-7082 blocked the elevation of IGF-1 secretion from shPHD2-GFP-ADSCs ( Figure 7K ). The decrease of cardiomyocyte apoptosis (caspase-3 activation and TUNEL + rate) induced by shPHD2-GFP-ADSC-CM was eliminated by BAY11-7082 or the IκBα dominant-negative mutant ( Figure 7L and 7M and Online Figure XI) .
The molecular bases of NF-κB-mediated secretion of IGF-1 have not been clearly defined. We demonstrated that IGF-1 mRNA was significantly increased by NF-κB stimulator lipopolysaccharide (Online Figure XIIA) . Three NF-κB binding sites in IGF-1 promoter were predicted using TFSEARCH program. A chromatin immunoprecipitation assay showed that the predicted site 2 of the IGF-1 promoter binded to NF-κB p50 (Online Figure XIIB) . These results indicate that NF-κB signaling can be activated by PHD2 silencing, and NF-κB activation may directly upregulate the transcription of IGF-1, increasing the secretion of IGF-1 in ADSCs.
Effects of HIF-1α Silencing and IGF-1 Neutralization on the Viability of shPHD2-GFP-ADSCs in Infarct Myocardium and Cardiac Function
Our in vitro data suggest that PHD2 silencing promotes the survival of ADSCs via an HIF-1α-dependent pathway and that IGF-1 secreted by shPHD2-GFP-ADSCs protects cardiomyocytes from apoptosis. We further determined the roles of HIF-1α and IGF-1 in the beneficial effects of shPHD2-GFP-ADSCs in vivo. HIF-1α silencing abolished the protection of shPHD2 against ADSC death after being injected into the myocardium ( Figure 8A ). However, the beneficial effects of shPHD2-GFP-ADSCs on post-MI infarction size, cardiac function, and cardiomyocyte apoptosis were not completely eliminated by HIF-1α silencing ( Figure 8B-8E and Online Figure XIII ). IGF-1 antibody injected with shPHD2-GFP-AD-SCs did not change ADSC survival ( Figure 8A ), but abolished shPHD2-GFP-ADSC-induced protection on cardiomyocytes ( Figure 8B) . Similarly, the beneficial effects of shPHD2-GFP-ADSCs on MI heart were not completely eliminated by blocking IGF-1 ( Figure 8C-8E and Online Figure XIII) . The combination of silencing HIF-1α and blocking IGF-1 treatment fully inhibited the therapeutic effects of shPHD2-GFP-ADSCs on MI heart ( Figure 8C-8E and Online Figure XIII) . Collectively, these results suggest that both enhancing ADSC survival and IGF-1 secretion are central to the beneficial effects of PHD2 silencing in ADSCs.
Discussion
Stem cell therapy to repair damaged myocardium has evolved into a promising treatment for ischemic heart disease. One of the limitations of stem cell therapy for heart disease is the low survival rate of transplanted stem cells. [4] [5] [6] Apoptosis has been implicated as the main contributor to the massive loss of donor cells. 26 Inflammation does not seem to be a factor accelerating the death of injected ADSCs because human ADSCs have a low immunogenic profile and elicit little inflammatory response. 21 Furthermore, an immunosuppressant drug was administrated in our study to achieve an equivalence of immune suppression as in allograft transplantation. 27 The major factor contributing to transplanted cell death seems to be the limited blood supply in the infarct zone that produces hypoxia and oxidative stress. This study explored a novel approach to enhance the viability of stem cells injected into this harsh environment.
We tested a novel hypothesis that reducing PHD2 abundance in ADSCs would enhance their survival and protective paracrine function when injected into the hostile environment of a post-MI heart. Transplantation of modified ADSCs with PHD2 silencing reduced infarction size and improved cardiac function in MI mice. In MI hearts, we measured ADSC survival, ADSC differentiation, cardiomyocyte survival, angiogenesis, fibrosis, and inflammatory responses after cell transplantation. We found that those beneficial effects of PHD2 silencing in ADSCs were associated with improved ADSC survival, reduced cardiomyocyte apoptosis, and decreased fibrosis. The experiments showed that PHD2 silencing reduced ADSC death via an HIF-1α-dependent pathway and that PHD2 silencing in ADSCs limited cardiomyocyte apoptosis through a protective paracrine mechanism mediated by enhanced IGF-1 secretion after the activation of NF−κB signaling (Online Figure XIV) . Our study provides strong support for approaches that enhance the survival and function of stem cells injected into hearts with limited blood supply.
PHD proteins were originally identified as oxygen-sensitive enzymes that transduce changes in oxygen availability into changes in the stability of HIF-1α, a master regulator of genes that promote survival in a low-oxygen environment. 28 There are 3 isoforms of PHD enzymes: PHD1, PHD2, and PHD3. 28 PHD2 is considered to be the key oxygen sensor and the primary HIF prolyl hydroxylase in the heart, which maintains low steady state levels of HIF-1α in normoxia by regulating HIF-1α degradation. 11 Previous studies have shown that PHD2 inhibition can improve cardiomyocyte viability and cardiac function in stressed hearts. Oral administration of a PHD inhibitor increased the microvascular density in infarcted rat hearts by stabilizing HIF-1α. 29 Direct intramyocardial injection of a short hairpin RNA plasmid targeting PHD2 led to significant improvement in angiogenesis and cardiac contractility after MI. 30 However, inhibiting PHD2 in all cells in the heart or deficiency of PHD2 in cardiomyocytes has yielded controversial results. Cardiomyocyte-specific PHD2 knockout mice ameliorated cardiac disease progression induced by MI for a period of 3 weeks, 31 but these mice developed more severe cardiac dysfunction when subjected to transverse aortic constriction or MI during a longer time period. 32 Long-term inactivation of PHD2 in cardiomyocytes leads to dilated cardiomyopathy and premature mortality. 33 These studies suggest that direct inhibition of PHD2 in cardiomyocytes could cause damaging effects, and the beneficial effect of PHD2 inhibition in the ischemic heart might be through noncardiomyocyte mechanisms (eg, by promoting angiogenesis). 29, 30 In this study, PHD2 activity was specifically modified in transplanted stem cells, avoiding the above-mentioned risks, and promoted cardiomyocyte survival. Our findings suggest that PHD2 silencing in transplanted ADSCs promotes cardiomyocyte survival via a protective paracrine mechanism mediated by IGF-1.
Mechanisms of Cardioprotection of ADSCs and shPHD2-GFP-ADSCs
A previous study showed that a nonspecific PHD inhibitor, dimethyloxalylglycine, significantly attenuated apoptosis of cultured mesenchymal stem cells induced by serum deprivation. 34 The exact mechanism mediating the beneficial effects of PHD2-mediated regulation of cell survival, however, is still not clear. We demonstrated that silencing of PHD2 significantly increased HIF-1α abundance, thereby promoting ADSC survival in the injured heart in vivo and ADSCs challenged with H 2 O 2 in vitro. These prosurvival effects on ADSCs were fully abolished with simultaneous HIF-1α silencing.
Because ADSCs did not differentiate into cardiomyocytes and ADSC differentiation into vascular cells was rare, it seems that the paracrine function was the major mechanism for the beneficial effects of injected ADSCs. Transplanted ADSCs with or without PHD2 silencing increase capillary density in post-MI hearts, likely by secreting angiogenic factors (VEGF, EGF, and hepatocyte growth factor) that may protect cardiomyocytes. PHD2 silencing did not further increase the secretion of these angiogenic factors and capillary density. Thus, the cardiomyocyte protection exerted by PHD2 silencing in ADSCs cannot be ascribed to increased capillary density. Our results suggest that PHD2 silencing increases the secretion of IGF-1 in ADSCs. IGF-1 provides the cardioprotective effects via reduction of cardiomyocyte apoptosis both in vitro and in vivo. IGF-1 is thought to reduce apoptosis of ischemic cardiomyocytes 35 by upregulating antiapoptotic protein B-cell lymphoma 2. 36 It was reported that exogenous stem cell transplantation might activate resident cardiac stem cells via a paracrine action. 37 Some paracrine factors secreted by stem cells, including IGF-1, may stimulate cardiac stem cell-mediated endogenous cardiac regeneration. 38 Thus, it is also possible that PHD2 silencing enhanced the ADSC-stimulated endogenous cardiac repair by increasing the secretion of proregenerative factors, such as IGF-1.
Silencing HIF-1α or neutralizing secreted IGF-1 only partially attenuated the therapeutic effect of shPHD2-GFP-ADSCs in vivo. Thus, stem cell survival and paracrine factors regulated by PHD2 silencing seem to function synergistically to promote the cardioprotective effects of transplanted ADSCs.
How Is IGF-1 Induced by PHD2 Silencing?
Our data show that HIF-1α silencing does not block the increase of IGF-1 induced by shPHD2, indicating that the enhancement of the paracrine function by shPHD2 is HIF-1α independent. These results are consistent with those showing that constitutive expression of HIF-1α in bone marrow stromal cells does not increase IGF-1. 39 The activation of NF-κB in mesenchymal stem cells leads to higher expression of prosurvival paracrine factors, including IGF-1. 24 Our data demonstrate that shPHD2 induces NF-κB activation probably by enhancing inhibitor of nuclear factor κB kinase activity and thus reducing IκBα, the native NF-κB inhibitor. We show that inhibition of NF-κB blocks the increase of IGF-1 secretion in shPHD2-GFP-ADSCs, and NF-κB activation increases the mRNA expression of IGF-1. Also, chromatin immunoprecipitation assays suggest that NF-κB p50 can bind to IGF-1 promoter. Collectively, these data indicate that activation of NF-κB can directly upregulate the transcription of IGF-1, ultimately increasing the secretion of IGF-1. This can, at least partially, explain the increased HIF-1α-independent paracrine effects that we observed.
Will PHD2 Silencing Effects Work in Other Types of Stem Cells?
PHD2, HIF-1, and NF-κB are ubiquitously expressed in various types of stem cells. As a cellular oxygen sensor, the regulatory effects of PHD2 on HIF-1 are well known in various cell types. 11, 28, 29 The association between PHD2 and NF-κB signaling was also reported in cancer cells 16, 23 besides ADSCs. In addition, nonspecific PHD inhibition attenuated apoptosis of cultured bone marrow mesenchymal stem cells induced by serum deprivation. 34 These studies indicate that the effect of PHD2 silencing is not specific to ADSCs and may work in other types of stem cells.
Conclusions
Our study effectively combines beneficial properties of PHD2 inhibition and advantages of stem cell therapy for cardiac repair. Silencing of PHD2 enhances the beneficial effects of ADSCs by increasing their viability and paracrine function. These beneficial effects are associated with HIF and NF-κB signaling pathways. PHD2 silencing could have a similar effect in other types of stem cells, and therefore, it could be a novel strategy for enhancing the efficacy of stem cell-mediated cardiac repair after MI.
What New Information Does This Article Contribute?
• PHD2 silencing in transplanted adipose-derived stem cells (ADSCs) promotes its therapeutic efficacy in postmyocardial infarction mouse hearts. • PHD2 silencing promotes the survival of transplanted ADSCs in myocardial infarction hearts through a hypoxia-inducible factor-1α-dependent pathway. • PHD2 silencing enhances the paracrine function of ADSCs to protect cardiomyocytes through nuclear factor-κB-mediated insulin-like growth factor-1 upregulation.
Stem cell transplantation to repair damaged myocardium is a promising, novel treatment for ischemic heart disease. However, a major limitation of this approach is poor survival and engraftment of stem cells in the ischemic heart. This study offers a new approach to overcome this limitation by silencing PHD2 in stem cells. PHD2 silencing promoted the survival and beneficial paracrine function of transplanted ADSCs, an abundant and easy-toacquire source of stem cells. In ADSCs, PHD2 regulates 2 key transcription factors, hypoxia-inducible factor-1α and nuclear factor-κB, under hypoxic and oxidative stress. PHD2 silencing enhanced stem cell viability by stabilizing hypoxia-inducible factor-1α and promoted stem cell paracrine-mediated antiapoptotic effects by inducing nuclear factor-κB-regulated insulin-like growth factor-1 expression. Stem cells with PHD2 silencing had significant beneficial effects on structural and functional remodeling in postmyocardial infarction hearts. Modulating the molecular pathways that determine stem cell survival and function may be critical in implementing stem cell therapy for diseased hearts.
Novelty and Significance
